亿帆医药(002019) - 2019 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2019 was ¥1,135,851,746, a decrease of 9.33% compared to ¥1,252,783,531 in the same period last year[3] - Net profit attributable to shareholders was ¥147,151,836, down 54.75% from ¥325,197,573 in the previous year[3] - Basic and diluted earnings per share were both ¥0.12, down 55.56% from ¥0.27 in the previous year[3] - The weighted average return on equity was 2.20%, a decrease of 2.70% from 4.90% in the previous year[3] - The company reported a loss of CNY 910,826.65 from financial derivatives during the reporting period[20] - Total operating revenue for the current period is ¥1,135,851,746, a decrease of 9.34% from ¥1,252,783,531 in the previous period[32] - Net profit for the current period is ¥141,058,138, down 55.32% from ¥315,314,372 in the previous period[33] - The company reported an operating profit of ¥183,508,768, a decline of 53.06% from ¥390,108,910 in the previous period[33] - Total comprehensive income for the current period is ¥135,327,158, down 57.00% from ¥315,370,493 in the previous period[34] - Total comprehensive income for the period was -94,775,644.49, compared to -25,858,619.58 in the previous period[37] Cash Flow - The net cash flow from operating activities was -¥46,570,212, a decline of 111.87% compared to ¥392,371,148 in the same period last year[3] - Cash inflow from operating activities totaled 1,094,165,304.34, down from 1,376,921,750.99 in the previous period[39] - Net cash flow from operating activities was -46,570,212.36, a significant decrease from 392,371,147.85 in the previous period[39] - Net cash flow from investing activities was -145,244,452.55, compared to 162,666,951.92 in the previous period[40] - Cash inflow from financing activities was 310,000,000.00, down from 390,732,875.00 in the previous period[40] - Net cash flow from financing activities was 109,726,677.98, an increase from 25,464,741.52 in the previous period[40] - The ending balance of cash and cash equivalents was 1,492,647,117.69, down from 1,826,495,289.23 in the previous period[40] - Cash and cash equivalents decreased by 92,747,869.02 during the period, compared to an increase of 545,797,484.31 in the previous period[40] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,711,576,615, a decrease of 0.65% from ¥9,774,884,477 at the end of the previous year[3] - The company's total current assets amounted to CNY 3.6019 billion, a decrease from CNY 3.6955 billion at the end of the previous period[24] - The company's cash and cash equivalents were CNY 1.5407 billion, down from CNY 1.6273 billion[24] - Accounts receivable increased to CNY 1.0341 billion from CNY 939.5 million, indicating a growth of approximately 10.1%[24] - Inventory rose to CNY 511.73 million, compared to CNY 477.83 million, reflecting an increase of about 7.1%[24] - Non-current assets totaled CNY 6.1097 billion, slightly up from CNY 6.0794 billion[25] - Total liabilities decreased from ¥2,887,212,314.92 to ¥2,686,768,915.51, a reduction of approximately 6.9%[26] - Owner's equity increased from ¥6,887,672,161.78 to ¥7,024,807,699.67, reflecting a growth of about 2.0%[27] - Current assets decreased from ¥1,948,458,212.16 to ¥1,832,984,997.12, a decline of approximately 5.9%[29] - Non-current assets increased from ¥4,224,599,361.23 to ¥4,256,874,510.03, showing a growth of about 0.8%[29] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 61,361[6] - The largest shareholder, Cheng Xianfeng, held 43.18% of the shares, amounting to 521,196,307 shares[6] - Net assets attributable to shareholders increased by 2.16% to ¥6,767,159,864 from ¥6,623,948,506 at the end of the previous year[3] - The total owner's equity attributable to the parent company increased from ¥6,623,948,506.23 to ¥6,767,159,864.28, reflecting a growth of approximately 2.2%[27] Government Support and Expenses - The company received government subsidies amounting to ¥5,477,831 during the reporting period[4] - Financial expenses decreased by 56.75% to ¥27,184,577.09, attributed to reduced exchange rate fluctuations and a decrease in USD asset balances[10] - The company experienced a 41.91% reduction in taxes and surcharges, amounting to ¥9,396,850.79, primarily due to a decrease in raw material sales prices[10] - The company paid 105,235,352.12 in various taxes during the period, compared to 171,967,527.05 in the previous period[39] Research and Development - Research and development expenses decreased to ¥23,192,859, down 29.83% from ¥33,070,043 in the previous period[32] - The company decided to terminate the development of three new drug projects due to increased risks and low chances of successful production[16] - The company terminated the high-end drug formulation project, resulting in unused raised funds totaling CNY 213.8453 million, which will be stored in a special account for future investment projects[17] Reporting and Compliance - The first quarter report of Yifan Pharmaceutical Co., Ltd. was not audited[43] - The company has implemented new financial instrument standards, new revenue standards, and new lease standards, but these adjustments do not apply to the current year[43] - There were no retrospective adjustments made to prior comparative data under the new financial instrument and lease standards[43] - The board of directors released the first quarter report on April 26, 2019[43] - The financial report adjustments were not applicable for the current year, indicating stability in reporting practices[43] - The company did not provide specific performance metrics or user data in this document[43] - There is no mention of future outlook or performance guidance in the provided content[43] - No new products or technologies were discussed in the financial report[43] - There are no details on market expansion or mergers and acquisitions in the document[43] - The report indicates a lack of significant changes in financial reporting standards affecting the current fiscal year[43]